Todos Medical Ltd.

166 articles with Todos Medical Ltd.

• Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics

  3/28/2023

  Todos Medical, Ltd. (OTCQB: TOMDF) today announced it has entered into a letter of intent with Acumen Diagnostics Pte Ltd of Singapore for its CLIA/CAP-certified clinical testing lab Provista Diagnostics to license the laboratory developed test (LDT) rights to commercialize the sepsis PCR-based diagnostic test AcuSept® in the United States.

• Todos Medical Begins Trading on the OTC Pink Marketplace

  3/27/2023

  Todos Medical, Ltd. today announced that its Ordinary shares will begin trading on the OTC Pink marketplace beginning on March 27, 2023 as a result of the Company’s closing bid price falling below $0.001 for 5 consecutive trading days, from March 20, 2023 through March 24, 2023.

• Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders

  3/13/2023

  Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, announced the Company has entered into a new agreement with holders of its convertible notes that provides for a 21-day moratorium on conversion of those convertible notes.

• Todos Medical Provides Corporate Update - February 23, 2023

  2/23/2023

  Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, provided a corporate update for shareholders.

• Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics

  2/14/2023

  Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has initiated a validation plan for PCR-based Avian Influenza A (H5N1, bird flu) human testing.

• Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022

  11/29/2022

  Todos Medical, Ltd. (OTCQB: TOMDF),  a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma was awarded oral and poster presentations at  World Antiviral Congress 2022.

• Todos Medical to Attend World Antiviral Congress

  11/22/2022

  Todos Medical, Ltd. (OTCQB: TOMDF),  a comprehensive medical diagnostics and related solutions company, today announced that company representatives will attend World Antiviral Congress 2022.

• Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network

  11/16/2022

  Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has entered into a direct 5-year agreement with Smart Automated Retail Network to supply immune support supplements for the expanding unattended automated retail market on an exclusive basis worldwide.

• Todos Medical Announces Third Quarter 2022 Financial Results

  11/15/2022

  Todos Medical, Ltd. announced financial results today for the third quarter of 2022, which ended on September 30, 2022.

• Todos Medical to Host Third Quarter 2022 Earnings and Business Update Conference Call on November 15, 2022

  11/14/2022

  Todos Medical, Ltd. announced that it will host the third quarter of 2022 earnings and business update conference call on November 15th, 2022 at 8:30am ET.

• Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A.

  11/10/2022

  Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, announced that it has terminated the Tollovid™ products license and distribution agreement it had with T-Cell Protect Hellas S.A.

• Todos Medical Provides Corporate Update - October 11, 2022

  10/11/2022

  Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, provided a corporate update for shareholders.

• Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics

  10/6/2022

  Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP laboratory, Provista Diagnostics, has successfully completed a pilot launch of the Company’s Suite of PCR Testing services in the rural city of Dunnellon, Florida.

• Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform

  9/30/2022

  Todos Medical, Ltd. today announced that it has received two Notices of Allowance from the United States Patent & Trademark Office (USPTO) for patent applications covering the Company’s Total Biochemical Infrared Analysis (TBIA) Fourier Transformed Infrared (FTIR) pan-cancer blood diagnostics platform.

• Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest™

  9/27/2022

  Todos Medical, Ltd. today announced that its majority-owned joint venture 3CL Pharma Ltd. received a Notice of Allowance issued by the USPTO for the Company’s proprietary SARS-CoV-2.

• Todos Medical Announces Preprint of Long COVID Case Study Participant with Confirmed Microclot and Hyperactivated Platelets who Benefitted from Tollovid

  9/15/2022

  Todos Medical, Ltd. reported the preprint in ResearchGate of a case study entitled “Consequences of Microclot Pathophysiology Underlying Long COVID Improved with Tollovid Supplementation."

• Todos Medical Partner NLC Pharma Assigns IP for Tollovir™, Tollovid™, and TolloTest™ into JV 3CL Pharma

  9/12/2022

  Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, announced that it signed an amendment to its agreement with its 3CL protease biology theranostics partner NLC Pharma, Ltd.

• Todos Medical CEO Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti

  9/9/2022

  Todos Medical, Ltd. released the Nasdaq MarketSite interview between Moneta Advisory Group’s Managing Partner Marc LoPresti and CEO Gerald Commissiong, discussing the impact of Long COVID on the economy and how SARS-CoV-2 viral persistence is damaging population-level immunity leading to the rise of viral outbreaks such as MonkeyPox.

• Todos Medical Expands COVID Onsite School Sample Collection to Include MonkeyPox Testing

  8/29/2022

  Todos Medical, Ltd. today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory, Provista Diagnostics, Inc., is expanding its onsite school sample collection programs for COVID-19 PCR testing to include MonkeyPox testing.

• Todos Medical Announces Saliva-Only MonkeyPox Testing at CLIA/CAP Clinical Lab Provista Diagnostics

  8/26/2022

  Todos Medical, Ltd. today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory Provista Diagnostics, Inc. is now offering saliva-only MonkeyPox testing.